Phase 1
Completed N=84
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
Healthy Subjects · Pharmacokinetics · Pharmacodynamics
Source: ClinicalTrials.gov NCT04183491 ↗
Enrolled (actual)
84
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcomePrimary: Area Under Effect Curve (AUEC) for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a — 7.82; 9.61; 11.08; 11.52 ng*day/mL
Summary
This study is designed to assess pharmacokinetics and pharmacodynamics of interferon beta-1a and peginterferon beta-1a across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies.
This is a randomized, placebo-controlled, single-dose, parallel arm study in 84 healthy subjects assigned to one of three dose groups (low, intermediate, and high) of each drug (interferon beta-1a and peginterferon beta-1a) or placebo.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under Effect Curve (AUEC) for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a |
7.82; 9.61; 11.08; 11.52; 18.20; 21.59 | — |
| PRIMARY Maximum Change From Baseline for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a |
3.50; 4.22; 4.93; 3.17; 5.01; 5.87 | — |
| SECONDARY Area Under the Curve (AUC) for Interferon Beta-1a and Peginterferon Beta-1a |
99.4; 223; 386; 970; 2226; 2740 | — |
| SECONDARY Maximum Concentration (Cmax) for Interferon Beta-1a and Peginterferon Beta-1a |
39.5; 90.8; 143; 191; 434; 509 | — |
| SECONDARY Area Under Effect Curve (AUEC) for Myxovirus-resistance Protein A (MxA) for Interferon Beta-1a and Peginterferon Beta-1a |
140; 172; 211; 458; 732; 1137 | — |
| SECONDARY Maximum Change From Baseline for Myxovirus-resistance Protein A (MxA) for Interferon Beta-1a and Peginterferon Beta-1a |
52.9; 62.9; 73.4; 86.7; 117.6; 175.5 | — |
| SECONDARY Pharmacodynamic Model Parameter, Emax (Maximum Effect), for Neopterin Area Under the Effect Curve Models With Interferon Beta-1a or Peginterferon Beta-1a |
13.3; 44.0 | — |
| SECONDARY Pharmacodynamic Model Parameter, ED50 (Half Maximal Effect Dose), for Neopterin Area Under the Effect Curve Models With Interferon Beta-1a or Peginterferon Beta-1a |
4.5; 84.1 | — |
| SECONDARY Pharmacodynamic Model Parameter, Emax, for Neopterin Maximum Change From Baseline Models With Interferon Beta-1a or Peginterferon Beta-1a |
5.7; 8.2 | — |
| SECONDARY Pharmacodynamic Model Parameter, ED50, for Neopterin Maximum Change From Baseline Models With Interferon Beta-1a or Peginterferon Beta-1a |
4.8; 44.3 | — |
Eligibility Criteria
Inclusion Criteria
- Subject signs an institutional review board (IRB) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization) before any study related procedures are performed.
- Subject is a healthy man or woman, 18 to 55 years of age, inclusive, who has a body mass index of 18.5 to 29.9 kg/m2, inclusive, at Screening.
- Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead electrocardiogram (ECG) results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
- Subject must have a negative test result for alcohol and drugs of abuse at screening and Check-in (Day -1).
- Female subjects must be of non-childbearing potential or, if they are of childbearing potential, they must: 1) have been strictly abstinent for 1 month before Check in (Day -1) and agree to remain strictly abstinent for the duration of the study and for at least 1 month after the last application of study drug; OR 2) be practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from at least 1 month before Check in (Day -1) until at least 1 month after the last application of study drug.
- Female subjects must not be pregnant or lactating before enrollment in the study.
- Male subjects must agree to practice 1 highly effective method of birth control (as determined by the investigator or designee) from at least 1 month before Check-in (Day -1) until at least 1 month after the end of study
- Subject is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.
Exclusion Criteria
- Subject has had previous exposure to the biologic Avonex or Plegridy.
- Subject is anemic (i.e., with Hct or Hgb considered clinically significant by Investigator or chronic history of anemia) or has any chronic condition(s) that may impact blood sample collection.
- Subject has a history of asthma.
- Subject has a history of anaphylaxis from environmental exposures such as peanuts or bee stings.
- Subject has an allergic history that includes urticaria, angioedema or respiratory coughing or bronchospasm.
- Subject has a history of severe local reactions or generalized erythema from skin allergen testing.
- Subject has used any prescription or nonprescription drugs (including aspirin or NSAIDs and excluding oral contraceptives and acetaminophen) within 14 days or 5 half-lives (whichever is longer) or complementary and alternative medicines within 28 days before the first dose of study drug.
- Subjects are currently participating in another clinical study of an investigational drug or are have been treated with any investigational drug within 30 days or 5 half-lives (whichever is longer) of the compound.
- Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff) within 6 weeks of Screening.
- Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee, chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours of dosing. Subjects must refrain from ingesting these throughout the study.
- Subject has any underlying disease or surgical or medical condition (e.g., cancer, human immunodeficiency virus [HIV], severe hepatic or renal impairment) that could put the subject at risk or would normally prevent participation in a clinical study. This includes subjects with any underlying medical conditions that put subjects at higher risk for coronavirus disease of 2019 (COVID-19) complications. Per current Center for Disease Control and Prevention (CDC) recommendations, this includes:
- People with chronic lung disease or moderate to severe asthma
- People who hav
Data sourced from ClinicalTrials.gov (NCT04183491). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.